The race to provide you with access to your genome is really heating up. Industry leader Illumina (NASDAQ: ILMN) has completed its first genome sequencing service for an individual at the low-low price of $48,000. That’s almost ten times what Complete Genomics plans to charge, but Illumina is offering the service directly to private individuals, not research groups. In fact, this is the first time any one person has had their genome sequenced for less than $50k. Illumina’s performance shows that it is still one of the forces to be reckoned with in whole human genome sequencing.
What are we to make of Illumina’s successful personalized genome sequencing service? It stacks up well against Knome’s KnomeCOMPLETE™ service which is perhaps the only other successful individual genome sequencing service on the market at the moment. Knome is trying hard to remain a contender in the field, but at $99.5k, it’s more than double Illumnia’s price. With comparable capabilities and results, price becomes the real determining factor between those two companies.
View Comments